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Abstract 
Highly active anti-retroviral therapy has proved successful in reducing morbidity 
and mortality associated with HIV infection though it has been linked to increased risk of 
cardiovascular disease.  To date the direct effects of the anti-retroviral drugs Efavirenz, 
Tenofovir and Emtricitabine on the vasculature relaxant response have not been elucidated, 
which impaired may predispose individuals to cardiovascular disease.  Increased cellular 
oxidative stress and overactivation of the DNA repair enzyme poly (ADP-ribose) 
polymerase (PARP) have been identified as central mediators of vascular dysfunction.  The 
aim of this study was to investigate whether exposure to Efavirenz, Tenofovir or 
Emtricitabine directly causes endothelial cell dysfunction via overactivation of PARP.   
Exposure of ex vivo male rat aortic rings or in vitro endothelial cells to Efavirenz but not 
Tenofovir or Emtricitabine impaired the acetylcholine-mediated relaxant response, 
increased cellular oxidative stress and PARP activity, decreased cell viability and increased 
apoptosis and necrosis.  Pharmacological inhibition of PARP protected against the 
Efavirenz-mediated impairment of vascular relaxation and endothelial cell dysfunction.  
Oestrogen exposure also protected against the Efavirenz-mediated inhibition of the vascular 
relaxant response, cell dysfunction and increased PARP activation.   In conclusion, 
Efavirenz directly impairs endothelial cell function, which may account for the increased 
risk of developing cardiovascular complications with anti-retroviral therapy.    
 
Keywords:  Efavirenz; Emtricibine; Tenofovir; PARP; cardiovascular; endothelial;  
Oestrogen. 
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Introduction 
Morbidity and mortality associated with HIV infection and subsequent development 
of AIDS has been dramatically reduced since the introduction of Highly Active Anti-
Retroviral Therapy (HAART) in 1993.  Anti-retroviral drugs which inhibit HIV reverse 
transcriptase were not only the first to be developed but have also continued to be a key 
component in the effectiveness of HAART.  The first anti-retroviral drugs to inhibit reverse 
transcriptase were nucleoside reverse transcriptase inhibitors (NRTI’s) such as the 
competative inhibitor azidothymidine (AZT), and these were joined by 
nucleotide/nucleoside reverse transcriptase inhibitors (NtRTI’s) such as Tenofovir and 
Emtricitabine.  These are analogues of the deoxynucleotides needed to synthesise the viral 
DNA competing with the naturally occuring deoxynucleotides, acting as substrates and 
being incorporated into the growing DNA chain, causing chain termination as they lack a 
3’-hydroxy group.  More recently non-competitive inhibitors of reverse transcriptase have 
been developed the non-nucleoside reverse transcriptase inhibitors (NNRTIs) which 
directly bind to the viral reverse transcriptase enzyme at a site other than the active site to 
inhibit its function, one example of the 1st generation of these drugs is Efavirenz. 
The success of HAART has been overshadowed by significant toxicities linked to 
anti-retroviral agents including increased risk of diabetes, atherosclerosis and 
cardiovascular complications.  NRTI’s have been linked to endothelial cell dysfunction 
through mitochondrial toxicity and increased cellular oxidative stress proposed to be 
mediated inhibition of DNA polymerase-γ which is crucial for mitochondrial replication 
and repair (1).   Increased cellular oxidative stress and overactivation of the DNA repair 
enzyme poly (ADP-ribose) polymerase (PARP) with subsequent cell depletion of high 
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energy phosphates and NAD have been shown to be a central mediator of vascular 
dysfunction in a variety of cardiovascular diseases (2).  The NRTI AZT has been shown to 
increase oxidative stress in both cardiomyocytes (3) and endothelial cells (4) subsequently 
increasing PARP activation in cardiomyocytes (3); likely to be the mechanism behind the 
increased risk of myocardial infarction (MI) found in the D:A:D study (5).  These 
cardiovascular side effects of NRTI’s was one of the driving factors to develop the newer 
NNRTI’s for HIV as they do not inhibit DNA polymerase-γ and were thought to have a 
reduced risk of mitochondrial toxicity. 
In 2006 Atripla was introduced, a combination of Efavirenz, Tenofovir and 
Emtricitabine in a single pill, to be taken once-a-day improving patient compliance.  
However, some cardiovascular complications have been identified with this combination 
pill.  In clinical studies endothelial cell function of patients on this drug combination, 
Efavirenz/Tenofovir/Emtricibine, as assessed by flow-mediated dilation of the brachial 
artery was found to be reduced as compared to other anti-retroviral drug combinations (6) 
suggesting an increased risk of cardiovascular disease.  Though the combination was found 
to increase the endothelial cell dysfunction as compared to Efavirenz alone (6), Tenofovir 
and Emtricibine have not been found to affect endothelial cell function or cardiovascular 
disease risk in clinical studies (5).  Efavirenz based regimens, however, have been shown to 
increase the risk of cardiovascular disease including an increased tendancy to develop 
atherosclerotic lesions (7, 8).  However, there are conflicting data on Efavirenz increasing 
the risk of myocardial infarction (MI) with the D:A:D study finding no increased risk (5) 
while a study in Canada demonstrated a significant risk of MI in patients on Efavirenz (9). 
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The direct effects of Tenofovir and Emtricitabine on in vitro endothelial cell 
function have not been investigated.  Tenofovir has been found to cause nephrotoxicity, 
however, had no effect on inflammatory, apoptotic or oxidative stress gene expression in 
coronary endothelial cells (10).  Emtricitabine alone has not yet been investigated to 
determine any in vitro endothelial cell damaging effects though in combination with 
Tenofovir has been shown to have no effect on leukocyte-endothelial cell interaction, a 
combination proposed to have a better vascular profile than other anti-retroviral regimens 
(11). 
Efavirenz has been shown to increase oxidative stress, MAPK and JNK 
phosphorylation and NF-κB activation in human coronary artery endothelial cells (12), 
effects proposed to be mediated by mitochondrial toxicity.  Efavirenz was also found to 
decrease the expression of the tight junctional proteins claudin-1, occludin, zonula 
occluden-1 and junctional adhesion molecule-1 with a subsequent increase in monolayer 
permeability (12).  Efavirenz has been shown to increase cellular oxidative stress and cause 
cell dysfunction in a variety of other cell types including hepatocytes (13, 14).  Indeed in 
HIV patients on Efavirenz increased levels of plasma F2 isoprostane concentrations which 
indicate increased oxidative stress have been observed (15).  These data suggest that 
Efavirenz may be the component of Atripla responsible for the endothelial cell dysfunction 
and subsequent increased risk of cardiovascular disease though the underlying pathology 
beyond increased oxidative stress has yet to be determined. 
Therefore the aim of this study was to examine the direct effects of the anti-
retroviral drug components of Atripla, Efavirenz, Tenofovir and Emtricitabine, on 
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endothelial cell function and investigate whether increased activation of PARP is 
responsible for any deleterious effects. 
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Methods 
Reagents 
Efavirenz, Tenofovir and Emticitabine were obtained from Sequoia Research 
Products Ltd. (Pangbourne, UK).  Acetylcholine chloride, bisBenzimide H 33342 
trihydrochloride, digitonin, dimethyl sulphoxide (DMSO), 2,7-dichlorofluorescin diacetate, 
endothelial cell growth supplement, oestrogen, heparin, nitro blue tetrazolium (NBT), 
phenylephrine hydrochloride, propidium iodide, sodium dodecyl sulfate (SDS), sodium 
nitroprusside and thiazolyl blue tetrazolium bromide (MTT) were obtained from 
Sigma/Aldrich (Poole, UK). 3H-NAD was obtained from PerkinElmer Ltd. (Windsor, UK).  
PJ-34 was purchased from Calbiochem (Nottingham, UK).  DMEM and Hams F12 culture 
media, non-essential amino acids, penicillin, streptomycin and fetal bovine serum (FBS) 
were obtained from GE Healthcare (Buckinghamshire, UK).  Sprague-Dawley rats used in 
the ex vivo studies were obtained from Charles River Laboratories (Kent, UK).  EA.hy926 
cells used in the in vitro studies were obtained from the UK distributor of American Type 
Culture Collection LGC Standards (Middlesex, UK).  All other chemicals were of reagent 
grade and obtained from Fisher Scientific (Loughborough, UK). 
 
Ex vivo 
Thoracic aorta from male or female Sprague-Dawley rats (180-220 g) were 
dissected and cleared of periadventitial fat and connective tissue.  Rings of 2-3 mm were 
cut and placed into Hams F12 medium supplemented with 3% FBS, endothelial cell growth 
supplement (0.03 mg/ml), heparin (50 U/ml) and 1% penicillin and streptomycin.  For the 
initial experiments male or female aortic rings were incubated with Hams F12 media alone 
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(control) or with Efavirenz, Tenofovir or Emtricitabine 1, 3 or 10 µM, for 2, 4 or 6 h at 
37°C with a 95% O2, 5% CO2 mix. Subsequent to these experiments male aortic rings were 
exposed to Efavirenz 10µM in combination with either an inhibitor of PARP (PJ-34 3µM), 
or oestrogen (10, 30 or 100 nM). 
Subsequent to the relevant incubation the aortic rings were mounted in organ baths 
filled with warmed (37°C) and gas-equilibrated (95% O2, 5% CO2) Krebs solution 
containing (in mM) CaCl2 1.6, MgSO4 1.17, EDTA 0.026, NaCl 130, NaHCO3 14.9, KCl 
4.7, KH2PO4 1.18, and glucose 5. Isometric tension of the rings was measured with force-
displacement transducers (Danish Myo Technology), digitised using PowerLab and 
displayed on a Macintosh computer. A preload tension of 1.5g was applied and the rings 
were equilibrated for 60 min, followed by measurements of the concentration-dependent 
contraction to phenylephrine (10-9 to 10-4 M) and in rings precontracted with phenylephrine 
(10-6M), relaxation to acetylcholine (10-9 to 10-4M). 
 
In vitro 
EA.hy926 cells (16)  were plated in a 12, 24 or 96 well plates and grown in DMEM 
media supplemented with 3% FCS.  Endothelial cells from PARP +/+ and PARP -/- mice 
were isolated and cultured as previously described (17).   The following measurements 
were then determined. 
 
Oxidative stress 
Oxidative stress was quantified by using the dichlorofluorescein (DCF) assay.  
Following the treatment protocol the experimental medium was removed and replaced with 
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100 µl DMEM medium without FCS containing 5 µM DCF and incubated for 30 min.  The 
DCF containing medium was removed, cells were washed twice with 100 µL PBS buffer 
before a final 100 µl of PBS buffer was added to each well and the plate placed in a 
fluroescence plate reader (Biotek Synergy) for 30 min with the wavelength of excitation set 
at 485 nm and emission set at 528 nm and readings taken every 5 min.  Data are expressed 
as % change in fluorescence at 30 min from time 0 before being compared to untreated 
cells and expressed as a % of control. 
   
Poly (ADP-ribose) polymerase (PARP) activity 
  PARP activity was measured as previously described (18).  Briefly, the medium 
was removed and replaced with 0.5 ml HEPES (pH 7.5) containing 0.01% digitonin and 
3H-NAD (0.5 µCi ml-1) and the cells incubated for 20 min at 37°C.  The cells were then 
scraped from the wells and placed in an Eppendorf tubes containing 200 µl of ice-cold 50% 
TCA (w/v), the tubes were then placed at 4°C.  After 4h the tubes were centrifuged at 
1800g for 10 min and the supernatant removed, the pellet was washed twice with 500 µl 
ice-cold 5% TCA. The pellet was solubilized in 250µl NaOH (0.1 M) containing 2% SDS 
overnight at 37°C, the PARP activity was then determined by measuring the radioactivity 
incorporated using a Wallac scintillation counter.    The solubilized protein (250 µl) was 
mixed with 5 ml of scintillant (ScintiSafe Plus, Fisher) before being counted for 10min.  
Results are expressed as a percentage of the PARP activity observed in untreated cells. 
 
Cell viability 
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 Cell viability was determined by the reduction of yellow MTT into a purple 
formazan product by mitochondrial dehydrogenases of metabolically active cells.  
Following the treatment period the experimental medium was removed and 100 µl MTT (1 
mg/ml) added.  After 1h incubation the MTT solution was carefully removed and the purple 
crystals were solubilized in 100 µl of DMSO.  The DMSO was transferred to an ELISA 
plate and absorbance measured at 550 nm with a 620 nm reference (19).  Results were 
expressed as a percentage of the absorbance observed in untreated cells. 
 
Apoptosis and necrosis levels 
 Apoptosis and necrosis were evaluated using Hoeschst/propidium iodide staining.  
Following 24h exposure to the appropriate treatment protocol the medium was removed 
and replaced with 100 µl of media containing 10 µg/ml of both Hoechst 33342 and 
propidium iodide.  Cells were then visualised using an inverted Axiovert 25 (Zeiss) 
fluorescent microscope set at excitation and emission wavelengths of 365 and 397 nm 
respectively.   Apoptotic cells being distinguished with characteristic nuclear fragmentation 
and intense staining of condensed chromatin, while necrotic cells were identified by red 
propidium iodide staining of the cytoplasm in cells with damaged plasma membranes.  
Results were expressed as % of apoptotic, necrotic or live cells with 500 nuclei being 
randomly counted in each treatment per experiment.    
 
Statistical analysis 
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 Results are presented as mean ± standard error of the mean (SEM).  Repeated 
measures analysis of variance or Student’s t-test was used to compare mean values as 
appropriate.  Differences were considered significant when p<0.05.  
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Results 
Efavirenz but not Tenofovir or Emtricitabine exposure results in concentration- and time-
dependent endothelial cell dysfunction 
 The effect of short-term exposure to anti-retroviral drugs on male rat endothelial 
cell function was investigated by exposing aortic rings to Efavirenz, Tenofovir or 
Emtricitabine at 1, 3, or 10 µM for 2, 4 and 6h.  Endothelial cell function was assessed by 
the ability of the endothelial cell to produce nitric oxide in response to ACh and cause 
subsequent vascular smooth muscle cell relaxation.   
Efavirenz exposure resulted in a time and concentration-dependent impairment of 
ACh-mediated male rat aortic ring relaxation (Fig. 1).  There was a significant increase in 
the EC50 concentration of acetylcholine following Efavirenz exposure as compared to 
untreated rings (Table Ia).  Tenofovir and Emticibine exposure had no effect on 
acetylcholine-mediated aortic ring relaxation (data not shown) with no significant changes 
in the EC50 for acetylcholine (Table I b and c). 
 Efavirenz, Tenofovir and Emtricabine exposure had no effect on the 
phenylepherine-mediated contraction or relaxation to the nitric oxide donor S-
nitrosoprusside of the aortic rings (data not shown).  
 
Efavirenz but not Tenofovir or Emtricitabine exposure results in loss of endothelial cell 
viability, increase in cellular oxidative stress and increase in apoptosis and necrosis levels. 
 Efavirenz caused a dose- but not time-dependent decrease in EA.hy926 endothelial 
cell viability as measured by the MTT assay (Fig 2).  Exposure of endothelial cells to 
Efavirenz for 24h also caused a dose-dependent increase in both apoptosis and necrosis 
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levels (Table IIa).  Neither Tenofovir nor Emtricibine had any effect on endothelial cell 
viability (Fig 2) or on apoptosis and necrosis levels (Table II b and c). 
Exposure of EA.hy926 cells for 24h to Efavirenz increased levels of oxidative stress 
by 30±7%, 28±6% and 32±12% for 3, 10 and 30 µM respectively (p<0.05 vs. untreated 
cells).  There was no increase in EA.hy926 cellular oxidative stress following exposure to 
Tenofovir or Emtricitabine even up to 100 µM (data not shown). 
 
Inhibition of PARP protects against Efavirenz-mediated endothelial cell dysfunction. 
 To determine whether Efavirenz-mediated activation of PARP mediates the 
observed endothelial cell dysfunction and loss of cell viability we pharmacologically 
inhibited PARP with PJ-34 (20). 
 Exposure to 10 µM Efavirenz for 4h significantly impaired endothelial cell function 
as assessed by acetylcholine-mediated vascular ring relaxation (Fig 3) and increased the 
EC50 for acetylcholine from 3.2±0.4 (x 10-8 M) to 10.7±3.2 (x 10-8 M)  (p<0.05).  Inhibition 
of PARP with PJ-34 (3 µM) significantly protected against the Efavirenz-mediated 
endothelial cell dysfunction (Fig 3) and partially reduced the EC50 for acetylcholine 
reducing it to 7.5±0.1 (x 10-8 M) (p<0.05 vs. Efavirenz 10 µM).  PJ-34 alone had no effect 
on vascular ring contraction induced by phenylephrine or relaxation by acetylcholine (data 
not shown). 
 To confirm that Efavirenz was affecting the cellular activity of PARP we carried out 
in vitro experiments exposing both the endothelial cell line EA.hy926 and primary mouse 
endothelial cells isolated from PARP +/+ and PARP -/- mice to Efavirenz and measured 
PARP activity. 
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 Efavirenz exposure dose- and time- dependently increased PARP activity in 
EA.hy926 cells (Fig 4) while Tenofovir and Emtricitabine had no effect on PARP activity 
(Table III).  Exposure of EA.hy926 cells to 10 µM Efavirenz for 4h increased PARP 
activity by almost 4-fold (Fig 5a), an effect significantly attenuated by simultaneous 
application of the PARP inhibitor PJ-34 (Fig 5a).  In addition 10 µM Efavirenz increased 
PARP activity 6-fold in PARP +/+ mouse endothelial cells (Fig 5b), an effect which was 
attenuated both by pharmacological inhibition with PJ-34 (3 µM) and in gene knockout 
PARP -/- mouse endothelial cells (Fig 5b).  Basal PARP activity in PARP -/- mouse 
endothelial cells was found to be 58.6±2% of that observed in PARP +/+ mouse endothelial 
cells. 
 
Efavirenz-mediated loss of EA.hy926 cell viability and increase in apoptosis and necrosis 
are reversed by inhibition of PARP. 
Inhibition of PARP with PJ-34 dose-dependently reversed the Efavirenz-mediated 
loss of endothelial cell viability (Fig 6).  PJ-34 (3 µM) also fully protected against the 
increased levels of apoptosis and necrosis observed following 24h exposure to 30 µM 
Efavirenz (Table IV). 
 
Effects of Estrogen on Efavirenz-mediated endothelial cell dysfunction.  
Aortic rings isolated from female rats exposed to Efavirenz for 4 (Fig 7a) or 6 h 
(Fig 7b) showed no endothelial cell dysfunction. With the EC50 for untreated rings being 
1.2±0.1 (x10-7 M) and for rings exposed to 10 µM Efavirenz for 4 and 6 h being 1.3±0.2 
(x10-7 M) and 1.1±0.7 (x10-7 M) respectivly (p>0.05 vs. untreated rings). 
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Simultaneous addition of oestrogen (10-100 nM) dose dependently protected 
against the endothelial cell dysfunction observed in male rat aortic rings following 4h 
expsoure to Efavirenz (10 µM) (Fig 7c).  Oestrogen alone had no effect on vascular ring 
contraction induced by phenylephrine or relaxation by acetylcholine (data not shown).   
Oestrogen significantly reduced the increased PARP activity observed in mouse endothelial 
cells exposed to 10 µM Efavirenz for 4h (Fig 7d). 
 
Discussion 
 The data presented here demonstrates for the first time that exposure of endothelial 
cells to the Efavirenz component of Atripla but not the Tenofovir or Emticibine causes 
direct cellular dysfunction associated with and mediated by an increased level of oxidative 
stress and activity of the DNA repair enzyme PARP.  Additionally, oestrogen was found to 
protect against Efavirenz-mediated endothelial cell dysfunction likely through its inhibitory 
effects on PARP activation which may explain why aortic rings isolated from female rats 
were found to be resistant to Efavirenz-mediated dysfunction. 
 Efavirenz is a 1st generation NNRTI designed not only to be more effective against 
HIV replication but also to reduce the mitochondrial toxicity associated with NRTI’s such 
as AZT and Stavudine cause endothelial cell dysfunction via inhibition of DNA 
polymerase-γ and subsequent oxidative stress (4).  Since NNRTIs like Efavirenz are non-
competitive inhibitors of HIV reverse transcriptase and do not inhibit DNA polymerase-γ 
they are proposed to be less likely to have mitochondrial toxicity increasing cellular 
oxidative stress.  However, Efavirenz has been found to in vitro to increase cellular 
oxidative stress in a variety of cell types including hepatocytes where it was found to have 
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mitochondrial toxic effects and inhibit mitochondrial complex I (14).  Efavirenz also 
increased cellular oxidative stress in endothelial cells (12), an effect we were able to 
confirm, again with mitochondrial toxicity likely to be responsible as there was a disruption 
of endothelial mitochondrial membrane potential following Efavirenz exposure (12).  
 Endothelial cell-mediated control of blood pressure is exerted via production of NO 
due to activation of eNOS, an NADPH-dependent enzyme (2).  Increased cellular oxidative 
stress in endothelial cells can significantly disrupt this primary function by impairing the 
availabilty of nitric oxide either directly by reacting with nitric oxide to produce 
peroxynitrite, or indirectly by affecting nitric oxide synthesis (2).  Efavirenz caused a dose- 
and time-dependent impairment of acetylcholine-induced nitric oxide-mediated relaxation 
of isolated aortic rings from male rats, an effect prevented by inhibition of the DNA repair 
enzyme PARP.  Direct measurement of PARP activity demonstrated a dose- and time-
dependent increase in enzyme activity in endothelial cells exposed to Efavirenz, which 
could be inhibited pharmacologically or by gene disruption.  Increased single strand DNA 
breaks, often caused by increased oxidative or nitrosative stress (2), result in an 
overactivation of PARP that, using NAD+ as a substrate, catalyzes the building of 
homopolymers of adenosine diphosphate ribose units (PAR polymers).  Though PARP 
activation has been linked to loss of cell viability and increased levels of necrosis and 
apoptosis (21), observed here in endothelial cells treated with Efavirenz, we do not believe 
that this can explain the observed cellular dysfunction due to the timescale involved.  The 
loss of endothelial cell function is observed following only 4 hours exposure to Efavirenz 
suggesting that the underlying pathological effect is being mediated through interference in 
the cellular pathways involved in vasorelaxation.   Previously overactivation of PARP in 
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endothelial cells has been shown to impair relaxation of the blood vessel (17) by 
suppression of eNOS activity through cellular depletion of NAD and NADPH levels (22).  
It is therefore likely that Efavirenz-mediated oxidative stress and subsequent PARP 
activation is responsible for impairing the activity of eNOS and hence vascular relaxation. 
The endothelial cell damaging effects of Efavirenz observed in vitro are at 
concentrations comparable to those seen clinically where the Cmax of Efavirenz has been 
reported to be 12.4±3.7 µM, and in as many as 20% of patients the Cmax reaching up to 50 
µM (23, 24).  The Cmin of Efavirenz has been reported to be 4.9± 2 µM (with a range 
between 1.6 µM and 8.7 µM) (25), therefore it may be Efavirenz-mediated endothelial cell 
dysfunction that accounts for the significantly increased risk of MI observed in patients (9).  
Endothelial cells exposed to Efavirenz showed decreased cell viability and 
increased levels of necrosis and apoptosis, effects which appear to be linked to PARP 
overactivation as indicated by the protection provided by pharmacological inhibition of 
PARP.  Though as indicated earlier it seems unlikely Efavirenz-mediated loss of 
endothelial cell viability and increase in cell death is responsible for the Efavirenz-mediated 
impairment of vasorelaxation due to the timescale of the deleterious effects, however, 
PARP overactivation appears to be the common mediator of Efavirenz-mediated 
endothelial cell damage.  PARP activation has been shown to cause disruption of 
mitochondrial membrane potential and ultimately destruction of the mitochondria as 
demonstrated by broken cristae and swelling (21).   This Efavirenz-mediated increase in 
cellular PARP activation may also explain the loss of mitochondrial function in endothelial 
cells reported following Efavirenz exposure (12).  
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PARP activation has been shown to mediate both necrosis and apoptosis (21).  
Depletion of cellular levels of NAD and high energy phosphates by overactivation of PARP 
has been shown to result in cellular necrosis (26), with inhibitors of PARP maintaining 
cellular pools of NAD, ATP, etc cellular necrosis can be prevented.  PARP activation via 
the production of the PAR polymer has also been shown to regulate apoptosis (26), the 
PAR polymer mediates the release of apoptotic proteins such as apoptosis inducing factor 
(AIF) (27) and cytochrome C (28) from the mitochondria.  Inhibition of PARP blocks both 
the AIF- and cytochrome C-mediated apoptotic pathways (21).  In hepatic cells Efavirenz 
was shown to reduce the mitochondrial levels of both cytochrome C and AIF (13) 
suggesting both PARP-regulated pathways are involved in Efavirenz-mediated cellular 
apoptosis hence this may be the reason PARP inhibition was so protective in endothelial 
cells.  Inhibition of PARP has also been linked to cellular protection from autophagy (29) 
through maintaining the activation of the AKT/mTOR pathway, Efavirenz increases 
autophagy in endothelial cells leading to apoptosis (30) and this pathway may also be 
blocked by PARP inhibition. 
The other two components of the ATRIPLA HAART medication Emtricitabine and 
Tenofovir showed no direct damaging effects on endothelial cell function, viability or 
levels of apoptosis and necrosis.  This is likely to be because whereas Efavirenz increased 
cellular oxidative stress and PARP activation we observed no such increase with either 
Tenofovir or Emtricitabine.  The concentrations of Emtricitabine and Tenofovir used in this 
study are relatable to the Cmax observed clinically being 7.28 µM and 1.03 µM (31, 32) 
respectively so our data does support the clinical evidence that Tenofovir and Emtricitabine 
have a good cardiovascular safety profile.  However, due to the combination of Efavirenz, 
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Emtricitabine and Tenofovir being found to have increased endothelial damaging effects 
than Efavirenz alone (6) the possibility of metabolites of Emtricitabine or Tenofovir having 
endothelial cell damaging effects or if these drugs affect the bioavailability and plasma 
concentration of Efavirenz cannot be ruled out. 
There seems to be a gender difference with regards to the incidence of 
cardiovascular side effects suffered by HIV patients on HAART, with women being less 
affected than men (33), however, this is reversed in post-menopausal female subjects on 
HAART who display an increased cardiovascular risk than their male counterparts due to 
the loss of their natural oestrogen protection (34).  Oestrogen has shown to be protective to 
the cardiovascular system against a wide variety of disease and mechanistic studies have 
linked this protection to modulating injury-induced inflammation, growth factor expression 
and oxidative stress.  Oestrogen has also been shown to affect PARP activation not directly 
inhibiting the enzyme but indirectly where PARP and the oestrogen receptor-α (ERα) 
interact when oestrogen is bound to the receptor (35).  Male mice treated with oestrogen 
have lower liver levels of PARP activation following lipopolysaccharide (LPS) treatment as 
compared to control (35) and castrated males have lower PARP activity in peripheral blood 
monocytes  (36).  This interaction between PARP and ERα has been shown to have a 
physiological role with PARP being a key regulator of ERα in controlling ERα 
transactivation and gene transcription (37).  Oestrogen has also been shown to protect 
against hydrogen peroxide-mediated necrosis and reduce PARP activity in bone marrow-
derived macrophages from male mice (38).   
Acetylcholine-induced nitric oxide-mediated relaxation of female aortic rings was 
unaffected by exposure to Efavirenz suggesting a protective effect of oestrogen exposure.  
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Gender differences in the vascular effects of LPS exposure for 3h have been observed 
previously with LPS causing a significant impairment of endothelial cell function of aortic 
rings isolated from male rats but had no effect on the endothelial cell function of aortic 
rings isolated from female rats (35).  Simultaneous application of oestrogen protected male 
aortic rings from Efavirenz-mediated dysfunction, as well as inhibiting Efavirenz-mediated 
PARP activation in endothelial cells.  Due to the short exposure time required for oestrogen 
to exert its endothelial cell protective effect against Efavirenz it is unlikely this is a gene 
transcription-dependent effect or increased levels of cellular protective anti-oxidant 
enzymes which oestrogen has been reported to induce (39).  It is very likely that the 
oestrogen-mediated inhibition of Efavirenz-induced PARP activation is via an interaction 
between ERα and PARP.  However, oestrogen and selective oestrogen receptor modulators 
such as Raloxifene have been shown to protect against oxidative stress-induced endothelial 
cell dysfunction by increasing the activity of eNOS by phosphorylation of the enzyme (40) 
and this cannot be ruled out as mediating part of the observed oestrogen protective effect.  
Similarly, though endothelial cell function in aortic rings from female rats may be protected 
from Efavirenz-mediated dysfunction because of an oestrogen-mediated reduction in PARP 
activation, these endothelial cells may also have higher levels of anti-oxidant defenses 
and/or eNOS activity.  However, it is clear that the effects of oestrogen on a cellular level 
protect endothelial cells from HAART drug-induced damage and this may explain the 
clinical observations that female HIV patients, at least pre-menopause, have less 
cardiovascular side effects (34).   
Based on the data presented here we conclude that exposure to Efavirenz but not the 
other components of Atripla, Tenofovir and Emtricitabine, leads to increased oxidative 
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stress, activation of PARP and impaired function of vascular endothelial cells.  This 
impairment of vasorelaxation may predispose HIV patients on Efavirenz based HAART 
regimens to development of cardiovascular complications including hypertension and 
increased risk of MI.  Indeed, overactivation of PARP may account for the impaired 
brachial artery flow-mediated dilation, an indicator of endothelial cell dysfunction, 
observed in HIV-infected patients on Efavirenz therapy (8).  We also propose that the 
observed gender differences in risk of developing cardiovascular complications in HIV 
patients on HAART may be a result of oestrogen-induced impairment of PARP activation 
protecting endothelial cell function.  With HIV infection becoming a chronic disease due to 
effective HAART understanding the underlying mechanisms of HAART-mediated 
cardiovascular complications as well as the impact of any physiological changes such as 
menopause on HAART side effects is essential.  Though Efavirenz as a 1st generation 
NNRTI has significantly less cardiovascular damaging effects than the original NRTIs 
there is still more research needed to improve the cardiovascular safety profile of this class 
of anti-retrovirals either by direct modification of the drugs or development of protective 
adjuvant therapies.  
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Figure legends 
 
Figure 1.  Exposure of ex vivo aortic rings to Efavirenz for 2h (A), 4h (B) or 6h 
(C) concentration-dependently impairs the ACh-relaxant response.  Thoracic aortic 
rings obtained from male Sprague-Dawley rats were exposed to 1, 3 or 10 µM Efavirenz 
for 2, 4 or 6h.  Following Efavirenz exposure ACh-induced endothelium-dependent 
relaxation was determined.  Data is expressed as mean ± SEM from 6-8 animals;  * p<0.05, 
**p<0.01 vs. untreated rings. 
 
Figure 2. Exposure of the EA.hy926 endothelial cell line to Efavirenz but not 
Tenofovir or Emtricitabine concentration-dependently reduced cell viability.  Data is 
expressed as mean ± SEM from 4 separate experiments with 6 replicates per experiment;  
** p<0.01 vs. untreated cells. 
 
Figure 3.  Efavirenz-mediated impairment of endothelium-dependent aortic ring 
relaxation is prevented by pharmacological inhibition of  PARP.  Exposure of thoracic 
aortic rings to 10 µM Efavirenz for 4h significantly impaired acetylcholine-induced 
endothelium-dependent relaxation, an effect prevented by simultaneous incubation of the 
rings with the PARP inhibitor PJ-34 (3 µM).  Data is expressed as mean ± SEM from 10 
animals;  **p<0.01 vs. untreated rings, ††p<0.01 vs. Efavirenz treated rings. 
 
Figure 4.  Exposure of EA.hy926 cells to Efavirenz for 2h (A), 4h (B) or 6h (C) 
concentration-dependently increased PARP activation.  EA.hy926 cells were exposed to 
 31 
Efavirenz (1, 3, or 10 µM) for 2, 4 or 6h prior to the measurements being taken.  Data is 
expressed as mean ± SEM from 4 separate experiments with 2 replicates per experiment;  
*p<0.05, ** p<0.01 vs. untreated cells. 
 
Figure 5.  Exposure of EA.hy926 cells (A) or mouse endothelial cells (B) to 
Efavirenz increased PARP activation an effect attenuated by inhibition PARP either 
pharmacologically or through gene deletion.  Inhibition of PARP pharmacologically 
with PJ-34 (3 µM) blocked the increase in PARP activity in EA.hy926 cells and mouse 
endothelial cells exposed to Efavirenz (EFV, 10 µM).  Additionally increased PARP 
activation was blocked in endothelial cells isolated from PARP-1 gene knockout mice 
exposed to Efavirenz (10 µM).  Data is expressed as mean ± SEM from 4 separate 
experiments with 3-6 replicates per experiment;  *p<0.05, ** p<0.01 vs. untreated cells 
†p<0.01 vs. Efavirenz treated cells. 
 
Figure 6.  Efavirenz-mediated loss of EA.hy926 cell viability is attenuated by 
PARP inhibition.  Data is expressed as mean ± SEM from 4 separate experiments with 3-6 
replicates per experiment;  *p<0.05, ** p<0.01 vs. untreated cells †p<0.01 vs. Efavirenz 
treated cells. 
 
Figure 7.  Exposure of ex vivo aortic rings from female rats to Efavirenz for 4h 
(A), or 6h (B)  had no effect on the acetylcholine-relaxant response.  Efavirenz-
mediated impairement of the ACh-relaxant response in ex vivo aortic rings from male 
rats (C) and increased PARP activity in EA.hy926 (D) was attenuated by Oestrogen.  
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Thoracic aortic rings obtained from female Sprague-Dawley rats were exposed to 1, 3 or 10 
µM Efavirenz for 4 or 6h following which acetylcholine-induced endothelium-dependent 
relaxation was determined (A and B).  Thoracic aortic rings obtained from male Sprague-
Dawley rats were exposed to 10 µM Efavirenz for 4h ± oestrogen (10, 30 or 100 nM) 
before acetylcholine-induced endothelium-dependent relaxation was determined (C).  
Mouse endothelial cells were exposed to Efavirenz (10 µM) ± oestrogen (100 nM) for 4h 
before PARP activity was measured (D).   Aortic ring data is expressed as mean ± SEM 
from 6-8 animals;  * p<0.05, **p<0.01 vs. untreated rings; †p<0.05, ††p<0.01 vs. 
Efavirenz treated rings.  Endothelial cell data is expressed as mean±SEM from 4 separate 
experiments with 3-6 replicates per experiment; ** p<0.01 vs. untreated cells ††p<0.01 vs. 
Efavirenz treated cells. 
 
 
 
 
Tables 
A 
 
 2h 4h 6h 
0 µM 0.03 ± 0.01 0.03 ± 0.003 0.05 ± 0.01 
1 µM Efavirenz 0.08 ± 0.02** 0.06 ± 0.01** 0.08 ± 0.01** 
3 µM Efavirenz 0.12 ± 0.02** 0.07 ± 0.01** 0.13 ± 0.03** 
10 µM Efavirenz 0.08 ± 0.02** 0.1 ± 0.03** 0.15 ± 0.03** 
 
B 
 
 2h 4h 6h 
0 µM 0.03 ± 0.01 0.04 ± 0.01 0.04 ± 0.01 
1 µM Emtricitabine 0.03 ± 0.01 0.04 ± 0.01 0.05 ± 0.01 
3 µM Emtricitabine 0.03 ± 0.01 0.04 ± 0.01 0.08 ± 0.02 
10 µM Emtricitabine 0.03 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 
 
C 
 
 2h 4h 6h 
0 µM 0.03 ± 0.01 0.02 ± 0.002 0.05 ± 0.01 
1 µM Tenofovir 0.06 ± 0.02 0.05 ± 0.004 0.04 ± 0.01 
3 µM Tenofovir 0.07 ± 0.01 0.04 ± 0.01 0.09 ± 0.02 
10 µM Tenofovir 0.05 ± 0.01 0.02 ± 0.01 0.05 ± 0.01 
 
 
Table I Effect of Atripla components on the acteylcholine-mediated relaxation 
EC50 (µM) of male aortic rings. Aortic rings were treated with increasing 
concentrations (1, 3 or 10 µM) of the individual components Efavirenz (A), 
Emtricitabine (B) and Tenofovir (C) for 2, 4 or 6h before measuring the 
acetylcholine-mediated relaxation of phenylepherine pre-contracted rings.  
Efavirenz but not Emtricibine or Tenofovir caused a dose- and time-dependent 
increase in the EC50 for acetylcholine.  Data are expressed as mean ± SEM of 
4-8 experiments.  * p < 0.05 and ** p < 0.01 when compared with untreated 
aortic rings. 
 
 
 
 
 
A 
 
Treatment % cells 
 Live Apoptotic Necrotic 
Control 96.92 ± 1.31 1.67 ± 0.80 1.42 ± 0.51 
3 µM Efavirenz 94.99 ± 1.66 3.06 ± 1.13 1.95 ± 0.61 
10 µM Efavirenz 91.59 ± 1.03* 4.86 ± 0.71* 3.55 ± 0.44* 
30 µM Efavirenz 75.14 ± 3.83** 17.34 ± 3.53* 7.52 ± 1.28* 
 
B 
 
Treatment % cells 
 Live Apoptotic Necrotic 
Control 97.02 ± 0.62 1.52 ± 0.20 1.47 ± 0.42 
3 µM Emtricitabine 96.83 ± 1.77 1.65 ± 1.01 1.53 ± 0.76 
10 µM Emtricitabine 96.29 ± 0.05 1.71 ± 0.04 2.01 ± 0.09 
30 µM Emtricitabine 95.54 ± 0.11 2.24 ± 0.21 2.23 ± 0.10 
 
C 
 
Treatment % cells 
 Live Apoptotic Necrotic 
Control 97.30 ± 1.20 1.36 ± 0.52 1.35 ± 0.68 
3 µM Tenofovir 97.27 ± 0.86 1.27 ± 0.47 1.47 ± 0.40 
10 µM Tenofovir 96.17 ± 2.03 1.75 ± 1.03 2.08 ± 1.00 
30 µM Tenofovir 97.22 ± 0.25 1.26 ± 0.08 1.53 ± 0.18 
 
 
Table II Effect of Atripla components on EA.hy926 cell death after 24 hours. 
Cells were treated with increasing concentrations (3, 10 or 30 µM) of the 
individual components Efavirenz (A), Emtricitabine (B) and Tenofovir (C) for 
24h.  Efavirenz but not Emtricibine and Tenofovir caused a dose-dependent 
increase in necrosis and apoptosis. Data are expressed as mean ± SEM of 3 
experiments (2 replicate wells per experiment).  * p < 0.05 and ** p < 0.01 
when compared with control endothelial cells. 
 
 
 
 
A 
 
Treatment PARP acticity (% untreated cells) 
 2h 4h 6h 
Control 100.0 ± 2.0 100.0 ± 1.4 100.0 ± 2.5 
1 µM Tenofovir 92.6 ± 1.3 95.2 ± 2.1 94.9 ± 3.3 
3 µM Tenofovir 96.0 ± 3.6 105.3 ± 2.4 98.9 ± 4.0 
10 µM Tenofovir 100.5 ± 8.5 94.7 ± 2.2 98.8 ± 4.5 
 
B 
 
Treatment PARP acticity (% untreated cells) 
 2h 4h 6h 
Control 100.0 ± 2.0 100.0 ± 1.4 100.0 ± 2.5 
1 µM Emtricitabine 96.0 ± 3.8 90.9 ± 5.8 102.1 ± 1.9 
3 µM Emtricitabine 99.2 ± 3.4 105.1 ± 1.9 99.2 ± 1.4 
10 µM Emtricitabine 97.7 ± 7.9 92.7 ± 3.4 98.2 ± 2.2 
 
 
Table III Effect of Tenofovir (A) and Emtricitabine (B) on PARP activity in 
EA.hy926 cells. Cells were treated with increasing concentrations (1, 3 or 10 
µM) of Tenofovir or Emtricitabine for 2, 4 or 6h before measuring PARP 
activity, neither drug had any significant effect on PARP activation. Data are 
expressed as mean ± SEM of 2 experiments (2 replicate wells per experiment). 
  
 
 
 
 
 
 
 
Treatment % cells 
 Live Apoptotic Necrotic 
Control 98.1 ± 0.3 1.2 ± 0.2 0.7 ± 0.1 
30 µM Efavirenz 78.00± 0.9** 15.3 ± 0.2** 6.7 ± 1.0** 
30 µM Efavirenz + 3 µM PJ-34 98.1 ± 0.3†† 0.8 ± 0.1†† 1.1 ± 0.3†† 
3 µM PJ-34 98.9 ± 0.1 0.7 ± 0.2 0.4 ± 0.1 
 
 
Table IV Effect of PJ-34 on Efavirenz mediated endothelial cell death after 24 
hours. Pharmacological inhibition of PARP with PJ-34 protected against 
Efavirenz-mediated increase in both cellular apoptosis and necrosis levels.  Data 
are expressed as mean ± SEM of 3 experiments (2 replicate wells per 
experiment). * p < 0.05 and ** p < 0.01 when compared with control untreated 
EA.hy926 cells and †† p < 0.01 when compared with efavirenz-treated cells.  
 







